Phase 3 N=39 Randomized Triple-blind Treatment

Therapies for Treatment-Resistant Panic Disorder Symptoms

Panic Disorder

Bottom Line

View on ClinicalTrials.gov: NCT00118417 ↗

Enrolled (actual)

Serious AEs

6.1%

Results posted

Jul 2009

Primary outcome: Primary: Change in Panic Disorder Symptoms, Phase 1 (Week 0 - Week 6) — 4.3 Points on a scale — p=0.0000

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Clonazepam (Drug); Sertraline (Drug); Cognitive behavioral therapy (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Massachusetts General Hospital
Primary completion: Oct 2007

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Panic Disorder Symptoms, Phase 1 (Week 0 - Week 6)	4.3	0.0000 sig
PRIMARY Change in Panic Disorder Symptoms, Phase 2 (Week 6 - Week 12)	2.36; 2.31	0.97
PRIMARY Change in Panic Disorder Symptoms, Phase 3 (Week 12 - Week 24)	3.78; 2.9	0.061

Summary

This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.

Eligibility Criteria

Inclusion Criteria

Diagnosis of panic disorder

Exclusion Criteria

History of bipolar disorder, schizophrenia, psychosis, or delusional disorders
Post-traumatic stress disorder diagnosis within 6 months prior to study entry
Current use of psychotropic medications
Current use of cognitive behavioral therapy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00118417). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.